New Biden EO Keeps Focus on Supply Chain Security for Critical Industries
Client Alert | 2 min read | 02.26.21
On February 24, 2021, President Biden issued the anticipated Executive Order (EO) on America’s Supply Chains, setting forth the Administration’s policy and goals with respect to strengthening and securing the country’s supply chain for critical products and services. Reflecting both an economic and national security focus, the EO directs the Assistant to the President for National Security Affairs (APNSA) and the Assistant to the President for Economic Policy (APEP) to coordinate the various agency actions contemplated by the EO, starting with a 100-day supply chain review by key agencies (including Commerce, Energy, Defense, and Health and Human Services) to identify risks and make specific policy recommendations as needed. The EO also calls on these agencies to prepare more comprehensive reports, due within one year, identifying limits and barriers to improving domestic capacity and resources.
Industries/areas of concern highlighted in the EO include:
- Semi-conductor manufacturing and advanced packaging supply chains;
- Critical minerals and other strategic rare earth elements;
- Information and communications technology;
- Pharmaceuticals and active pharmaceutical ingredients (and more generally, supply chains for public health and biological preparedness).
In addition, the EO specifically directs the agencies to evaluate risks posed by the various supply chains’ reliance on digital products (and associated cybersecurity vulnerabilities), as well as risks posed by a lack of domestic capabilities.
As with the recent Made in America executive order, the EO articulates a policy of strengthening and rebuilding critical domestic supply chains with a view toward promoting small businesses, promoting racial equity and fair wages, and addressing the effects of climate change.
The EO directs these agencies to consult outside stakeholders such as industry, labor unions, and non-governmental organizations in carrying out their responsibilities, which will provide opportunities for interested parties to engage in the review process.
A focus on strengthening critical supply chains enjoys bipartisan support, although it remains to be determined what exact measures the Administration and/or Congress will ultimately pursue. Companies with supply chains implicated by the EO should consider proactive steps to review their own global operations and engage with industry and government stakeholders to foster an evidence-based discussion and shape potential recommendations and outcomes.
Insights
Client Alert | 5 min read | 01.27.25
After Trump Executive Orders, FDA Removes Diversity Guidance From Website
Days after President Trump issued an executive order (EO) taking aim at diversity, equity, and inclusion (DEI) programs and prohibiting federal recognition of gender identity apart from biological sex, previously issued draft guidance on diversity in clinical trials was removed from the website of the U.S. Food and Drug Administration (FDA). While the removed guidance was in draft form, it is highly unusual for FDA to revoke or alter draft guidance without issuing a statement or further guidance. This move raises questions about the applicability of statutory obligations to submit clinical trial Diversity Action Plans and the agency’s current thinking on best practices for clinical development.
Client Alert | 8 min read | 01.27.25
Client Alert | 5 min read | 01.27.25
Client Alert | 2 min read | 01.27.25
State Department Pauses Almost All Foreign Assistance Funding